Aflibercept is a recombinant fusion protein that acts as a soluble decoy receptor for vascular
endothelial growth factor (VEGF), a key regulator of angiogenesis. It binds to all isoforms of …

Purpose Treatment for metastatic colorectal cancer (mCRC) commonly involves a
fluoropyrimidine-based chemotherapy regimen such as infusional fluorouracil, leucovorin …

Aflibercept (Zaltrap (®): aflibercept is a recombinant fusion protein, anti-angiogenic, which
blocks activation of VEGF and PIGF receptor), obtained its European approval February 2 …

Introduction: Colorectal cancer (CRC) is currently the third most common cancer worldwide,
with up to 1 million new cases diagnosed each year. Despite improvements in clinical …

Background: Metastatic colorectal cancer (mCRC) represents a substantial health burden
globally and an increasing challenge in Asian countries. Treatment options include …

Purpose The antiangiogenic agent aflibercept (ziv-aflibercept in the United States) in
combination with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) significantly improved …

Background The objectives of this study were to evaluate the safety profile of aflibercept and
health-related quality of life (HRQL) in patients with metastatic colorectal cancer (mCRC) …

Purpose: Aflibercept is a recombinant fusion protein of the VEGF receptor (VEGFR) 1 and
VEGFR2 extracellular domains. We assessed the safety and efficacy of aflibercept in …

Purpose In the VELOUR study, aflibercept+ FOLFIRI regimen resulted in improved survival
in metastatic colorectal cancer (mCRC) patients who progressed after oxaliplatin. The use of …

Introduction Anti-angiogenic drugs are an efficacious class of therapy in the treatment of
patients with metastatic colorectal cancer (mCRC). Aflibercept, a vascular endothelial growth …